Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals

MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicin...

Related Keywords

Miami ,Florida ,United States ,Japan ,Delaware ,Derek Cole ,Exchange Commission ,Longeveron Inc ,Exchange Commission On ,Drug Administration ,Advocacy Group Partnership ,Nasdaq ,Wa El Hashad ,Hypoplastic Left Heart Syndrome ,Rare Pediatric Disease ,Orphan Drug ,Fast Track ,Core Business Objectives ,Main Value Driver ,Manufacturing Capabilities ,Resource Management ,Japan Aging Related Frailty ,Capital Strategy ,Aging Related Frailty ,Term Investor Engagement ,Financing Prudence ,Aligned Capital Allocation ,Group Partnership ,Mild Alzheimer ,Private Securities Litigation Reform Act ,Nasdaq Capital Market ,Annual Report ,Quarterly Reports ,Current Reports ,